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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: The difference in blood pressure changes in the AA vs. the non-AA
subgroup may be due to greater BP reductions in the AA sham control group. This
greater than expected drop in BP in the sham control group suggests a post-
randomization interaction with an exposure that impacted BP lowering. Further
investigation of factors that may impact sham response is warranted.African
American
Denervation
(n¼90)
African
American
Sham
(n¼50)
P
value
Non-African
American
Denervation
(n¼273)
Non-African
American
Sham
(n¼121)
P
value
Ofﬁce BP
SBP
Baseline
180.6  16.4 183.9  19.8 0.294 179.5  16.0 178.6  15.3 0.611
3 month
change
-16.0  22.0 -13.7  21.8 0.546 -15.5  24.5 -14.6  22.4 0.710
6 month
change
-15.5  25.4 -17.8  29.2 0.641 -15.2  23.5 -8.6  24.8 0.012
DBP
Baseline
101.1  17.0 104.4  16.5 0.264 95.0  16.2 96.6  14.9 0.368
3 month
change
-8.3  11.9 -4.9  11.6 0.114 -6.9  12.0 -4.5  11.1 0.067
6 month
change
-8.2  12.1 -6.8  17.1 0.631 -6.0  11.8 -3.7  11.8 0.086
ABPM
SBP Baseline 160.4  13.8 162.7  16.2 0.384 158.7  13.0 158.2  14.8 0.729
6 month
change
-7.6  16.3 -6.7  18.4 0.782 -6.5  14.8 -4.0  16.8 0.158
DBP
Baseline
92.7  14.6 95.3  13.2 0.308 86.6  13.4 89.1  14.6 0.094
6 month
change
-4.8  9.9 -3.6  11.6 0.542 -3.89  9.0 -2.9  9.5 0.337TCT-406
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Background: Renal denervation is a new treatment for resistant hypertension. As new
systems are introduced, the incidence of acute renal artery wall injury with relation to
the denervation method is unknown. We aimed to investigate by quantitative angi-
ography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT),
the acute repercussion of renal denervation for treatment of resistant hypertension on
the renal arteries treated with 4 different systems.
Methods: Nineteen patients underwent bilateral renal denervation in two centers with
4 different systems: Symplicity (n¼6), Paradise (n¼5), Oneshot (n¼6) and
Vessix V2 (n¼2). Analysis included quantitative angiography pre- and post-
procedure, morphometric measurements by IVUS pre- and post-procedure, and assess-
ment of vascular trauma (dissection, oedema, or thrombus) by OCT after denervation.
Results: No signiﬁcant differences between pre- and post-procedure were observed in
lumen and vessel dimensions by quantitative angiography or IVUS. By post-
denervation OCT, dissection was seen in 12 arteries (37.5%), 11 of which were treated
with balloon-based denervation catheters. Thrombus and oedema were detected in 26
(81.2%) and 22 arteries (68.8%), respectively. In arteries with any dissection by OCT
the balloon-to-artery ratio was higher (1.240.13 versus 1.100.11, p¼0.01), while
6 out of 7 arteries (86%) treated with balloon catheters with a balloon-to-artery
ratio>1.18 had evidence of dissection by OCT. In arteries with lumen contour
irregularities or dissection by angiography there was higher incidence of dissection
and a trend for higher thrombus (dissection: 66.7% versus 15.8%, p< 0.01; thrombus:
100.0% versus 68.4%, p¼0.06).
Conclusions: A varying extent of vascular injury was observed after renal denervation
in all systems. Dissections were observed mainly in arteries treated with balloon-based
denervation catheters and were associated with a higher balloon-to-artery ratio and
vessel wall irregularities on post-procedural angiogram.
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Background: Catheter-based renal denervation (RDN) emerged as a therapeutic
option fo r resistant hypertension patients. Nerve “regrowth” has been questioned. We
aimed to characterize the renal nerve response following RDN acutely and long term.B120 JACC Vol 64/11/Suppl B j September 13–17, 2014Methods: Swine underwent bilateral RDN and followed for 7, 30, and 180 days.
A representative section of each time point was selected for H&E and immunohis-
tochemical (IHC) analysis. IHC consisted on S100 (Schwann cell), Tyrosine hy-
droxylase (TH; efferent motor renal nerves), calcitonin gene-related peptide (CGRP)
and substance P (SP); (CGRP and SP afferent sensory renal nerves).
Results: H&E displayed the typical acute (7 days: nerve necrosis, distal atrophy) and
chronic (180 days: nerve ﬁbrosis) nerve injury. At 180 days we could observe evi-
dence of nerve remodeling and tentative regeneration, morphological recovery of
S100, and TH staining and to variable degrees of CGRP and SP staining. However,
there was evidence of TH and S100 staining spill over and extension of neural bundles
within and across the thickened perineurium, forming neuroﬁbrous tangles highly
reminiscent of amputation neuromas (neuromatous regeneration). IHC revealed that
the nerve displayed early signs of TH and S100 positive ﬁbers within and beyond the
ﬁbrous perineurium as early as 7 days following RDN. This perineurial neuromatous
proliferation becomes more evident at longer time points. At 180 days, these neu-
romatous tangles became very prominent with affected nerves completely remodeled
into neuromatous proliferative bundles.
Conclusions: It has been previously demonstrated in renal transplant models that
sympathetic nerves have the ability to regenerate. Furthermore,there are evident signs
of increased nerve count in swine model at longer time points following RDN.
However this is the ﬁrst evidence that this “regenerative nerve attempt” occurs as early
as 7 days following RDN therapy and is progressively increasing over time, resulting
in the formation of poorly organized tangles of nerve ﬁbers, Schwann cells and
connective tissue. This is the ﬁrst complete histological characterization of neu-
romatous nerve regrowth following RDN.
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Background: The SYMPLICITY Spyral ﬁrst-in-man (FIM) study investigated the
safety and effectiveness of the Spyral multielectrode renal denervation catheter to
lower blood pressure in patients with resistant hypertension.
Methods: The prospective, open label Spyral FIM study enrolled 50 subjects with
resistant hypertension deﬁned as an ofﬁce systolic blood pressure of 160 mm Hg
(150 mm Hg for type 2 diabetics) despite adherence to an antihypertensive regimen
of3 drug classes (ideally including a diuretic). Subjects with an estimated glomerular
ﬁltration rate of < 45 mL/min/1.73m2, type 1 diabetes mellitus, renal artery stenosis of
>50%, renal artery aneurysm, and prior renal artery intervention were excluded. The
protocol speciﬁed one denervation treatment per artery via delivery of 4 simultaneous
60 seconds ablations per artery. The safety endpoint is a composite of vascular com-
plications, renal artery reintervention, new onset end stage renal disease, death,
myocardial infarction, signiﬁcant embolic event resulting in end-organ damage, hy-
pertensive crisis and new renal artery stenosis. Effectiveness is measured by change in
ofﬁce BP from baseline at 1, 3, 6, and 12 months and annually thereafter.
Results: The mean age of subjects was 63 years, 64% were men, 46% had type II
diabetes mellitus, and baseline estimated glomerular ﬁltration rate was 85.1 
32.1 mL/min/1.73m2. Baseline systolic and diastolic blood pressure was 181 
17 mm Hg and 95  12 mm Hg, respectively, and the mean number of antihyper-
tensive drug classes was 4.5  1.1. The mean number of ablations per artery was 3.25.
Three access-site pseudoaneurysms and 1 myocardial infarction occurred during
6 months follow-up. No new renal artery stenosis or hypertensive emergencies
occurred, and there was no clinically meaningful change in renal function. The change
in ofﬁce-based blood pressure was -19.9  25.0/-7.3  11.5 mm Hg at 6 months,
p< 0.001.
Conclusions: Renal denervation using the Spyral multielectrode catheter is safe and
results in signiﬁcant reduction of ofﬁce blood pressure from baseline. 12-month
follow-up results will be available for presentation in September.
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Background: The Symplicity HTN-3 recently failed to meet its primary efﬁcacy
endpoint in blood pressure reduction. The device used in this study as well as all other
denervation systems only ablate peri-arterial nerves. The Verve Medical system di-
rects radiofrequency energy to the renal pelvic space where the preponderance of
afferent nerves originate and are closely accessible. We have previously demonstrated
the feasibility of the Verve Medical NephroBlate to ablate these nerves.
Methods: We developed a protocol to treat a small number of patients (n¼3, 4 kid-
neys) undergoing elective nephrectomy. After submission to the hospital institutional
review board and after patient informed consent we treated three patients with endj TCT Abstracts/Hypertension Therapies Including Renal Denervation
